Stock Events

Stock Events

Verona Pharma 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline develops respiratory drugs, directly competing with Verona Pharma's treatments for respiratory diseases.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca has a strong portfolio in respiratory and inflammation treatments, overlapping with Verona Pharma's focus areas.
Champion Industries
CHMP
Mkt Cap1,129
Chiesi Farmaceutici, though not listed on a US exchange, competes in the global respiratory market, similar to Verona Pharma's target.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals focuses on cystic fibrosis, a specific area within the broader respiratory disease market that Verona targets.
Insmed
INSM
Mkt Cap25.89B
Insmed Incorporated offers therapies for rare lung diseases, competing in the niche market that Verona Pharma aims to serve.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap42.46B
Teva Pharmaceutical Industries has a broad portfolio that includes respiratory treatments, making it a competitor.
Novartis
NVS
Mkt Cap292.35B
Novartis AG has a diverse range of pharmaceuticals, including treatments for respiratory conditions, competing with Verona Pharma.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. develops drugs for various conditions, including respiratory diseases, making it a competitor.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. has a wide array of pharmaceutical products, including those for respiratory diseases, competing with Verona Pharma.
Biogen
BIIB
Mkt Cap32.28B
Biogen Inc. focuses on serious medical conditions, including respiratory diseases, though its main focus is on neurological conditions.

About

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Show more...
CEO
Dr. David Scott Zaccardelli Pharm.D.
Employees
209
Country
United Kingdom
ISIN
GB00BYW2KH80

Listings

MU
DE
I9SA.MU
STU
DE
I9SA.STU
STU
DE
I9S1.STU

0 Comments

Share your thoughts

FAQ

What is Verona Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Verona Pharma stocks are traded under the ticker I9S1.STU.
How many employees does Verona Pharma have?▼
As of September 04, 2026, the company has 209 employees.
In which sector is Verona Pharma located?▼
Verona Pharma operates in the Health & Wellness sector.
When did Verona Pharma complete a stock split?▼
Verona Pharma has not had any recent stock splits.
Where is Verona Pharma headquartered?▼
Verona Pharma is headquartered in London, United Kingdom.